Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Phase 2 N=17 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
Phase 2 N=2 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Phase 2 N=77 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants
Phase 2 N=29 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Phase 2 N=19 Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Phase 1 N=18 MK-3475/BCG in High Risk Superficial Bladder Cancer
Bladder Cancer
Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants
Phase 2 N=49 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Phase 2 N=113 Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Locally Advanced or Metastatic Urothelial Bladder Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC) — 24.0 Percentage of participants — p=< 0.0001
Phase 2 N=43 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Bladder Cancer
Primary: Objective Response Rate (ORR) — 1; 2 Participants
Phase 2 N=63 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Primary: Complete Response (CR) Rate for UGN-102 Treatment — 65.1 percentage of patients
Phase 2 N=83 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Urothelial Carcinoma · Bladder Cancer
Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants
Phase 2 N=13 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Phase 2 N=15 Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
Phase 2 N=19 Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
Phase 2 N=45 Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
Bladder Cancer
Primary: Progression Free Survival — 8.2 months
Phase 2 N=60 Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
Bladder Cancer
Primary: Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen — 38; 53 Percentage of Participants
Phase 2 N=69 Cabozantinib for Advanced Urothelial Cancer
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants
Phase 2 N=76 Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Bladder Cancer
Primary: Clinical Complete Response (CCR) Rate — 43 Percentage of participants
Phase 2 N=20 Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage IV Bladder Urothelial Carcinoma AJCC v7
Primary: Progression-free Survival (PFS) — 11.4 months
Phase 2 N=28 Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Bladder Cancer
Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants
Phase 3 N=406 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
Bladder Cancer
Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01
Phase 2 N=28 Bristol Bladder Trial
Infiltrating Bladder Urothelial Carcinoma
Primary: Overall Pathological Response Rate — 57.7 % of participants
Phase 3 N=931 A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Bladder Cancer
Primary: Overall Survival (OS) — 10.6; 11.1; 8.2; 8.9 Months — p=0.4134
Phase 2 N=172 Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Recurrent Bladder Urothelial Carcinoma · Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants
Phase 1 N=12 Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Urinary Bladder Neoplasms
Primary: Number of Grades 1-5 Adverse Events — 12; 3; 15; 9 adverse events
Phase 2 N=37 Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
Phase 2 N=50 Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
Neoplasms
Primary: Objective Tumour Response According to RECIST Criteria — 14.0 Percentage of participants